Beryl Whitman
Founder & Chief Executive Officer Khosen Bio
Since the 2021 brain tumor diagnosis of a family member, Beryl has traveled the world to identify leading experts in oncology, neurology, immunology, biotech pioneers and big pharma CSOs, forming the foundation of Khosen Bio. He has assembled a world-class team and rallied them around this singular focus: transforming the therapeutic landscape of brain cancer with personalized neoantigen vaccines.
Seminars
Neoantigen selection and validation remains a major bottleneck for the industry, requiring accurate prioritisation of tumour-specific mutations that are processed, presented, and capable of driving robust T-cell responses. Advanced bioinformatics tools such as whole exome/genome sequencing and multi-omics integration, provide a structured approach to identifying and ranking candidate targets based on expression, clonality, and HLA presentation. With the rise of AI and machine learning, this process can help further refine immunogenicity prediction and accelerates target prioritisation. This workshop will explore how combining bioinformatics and AI-driven strategies can overcome key challenges in neoantigen validation and enhance the development of effective cancer immunotherapies.
This workshop will gather experts to discuss:
- Integrate multi-omics data to improve target validation and accuracy
- Apply AI and machines learning models to enhance immunogenicity prediction
- Analyse end-to-end neoantigen identification workflows to streamline your neoantigen selection
- Explore strategies for experimental validation to overcome hurdles with standard validation techniques
- Utilise bioinformatics data to precisely translate it into clinically actionable immunotherapy programs
